Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease - Seite 2
Angion expects to report cash and cash equivalents of greater than $60 million at the end of the second quarter.
About Angion
Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known
limitations. Angion’s lead product candidate is ANG-3070, a highly-selective oral tyrosine kinase receptor inhibitor. A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is
planned to start in 2022. Additionally, Angion has preclinical programs focused on a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please
visit www.angion.com.
Lesen Sie auch
Forward Looking Statements
Statements contained in this press release regarding matters that may occur in the future are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995, including but not limited to statements in this press release regarding the potential of ANG-3070 as a treatment for idiopathic pulmonary fibrosis (IPF), Angion’s plans to initiate a Phase 1b
study of ANG-3070 in IPF in 2022, and Angion’s expectation to report cash and cash equivalents of greater than $60 million at the end of the second quarter. Such statements are subject to risks and
uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. In particular, the following factors, among others, could cause results
to differ materially from those expressed or implied by such forward-looking statements: Angion’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of
ANG-3070 and its other product candidates; the accuracy of Angion’s estimates relating to its ability to initiate and/or complete clinical trials; the results of preclinical studies may not be
predictive of future results; the costs of clinical trials may exceed expectations; Angion’s ability to raise additional capital; and the effects of COVID-19 on Angion’s clinical programs and
business operations. For a fuller description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, see Angion’s Quarterly Report
on Form 10-Q for the quarter ended March 31, 2022, filed with the Securities and Exchange Commission on May 16, 2022, especially under the caption “Risk Factors,” as well as other documents that
may be filed by Angion from time to time with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date of this release. Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.